Raloxifene is a drug registered for the treatment and prevention of osteoporosis and risk of invasive breast cancer in postmenopausal women [45], ER agonist in the bone, liver and cardiovascular system, and ER antagonist in reproductive tissues [46]. This evidence concerns the gene ESR1 and invasive breast carcinoma.